What stood out at TCT in Orlando?
Orlando – There have been numerous useful insights into the future of next generation of CAR T cell therapies at the Transplantation and Cellular Therapy Meeting (TCT) that’s currently underway here in Florida.
TCT (formerly BMT Tandem) is the combined meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).
It should come as no surprise that the transplant community have embraced cellular therapies.
As we start what experts such as Carl June refer to as “the decade of cell therapy,” what does the next generation of CAR T cell therapy likely look like and how will we overcome some of the challenges associated with this approach?
In this post we’re following developments in the field, and sharing what we’ve learnt so far from thought leaders at the TCT meeting. This is the latest in our recent mini-series of posts on future developments in cellular therapy.
To gain insights from our oncology coverage and get a heads up on our latest analysis and commentary subscribers can log-in or you can click to gain access to BSB Premium Content.
CAR T cell therapy for solid tumours is the cancer new product development equivalent of the quest for the “Holy Grail.” It remains one of the cell therapy challenges of the coming decade.
Light inspires and illuminates
In this post we shine the light on one of the world’s leading cell therapy experts who is taking on that challenge.
Most of our posts are what is known in the business as “long-form” and this one is no exception; it’s over 7,000 words long and offers a veritable smorgasbord of insights into new cell therapies for blood cancers and solid tumours, novel targets, as well as future directions, including a company in stealth mode…
Curious to learn more about this important topic on cracking the code and the quest to find solutions?
Then consider supporting independent science journalism by joining an exclusive group of readers around the world in academic medicine and industry who read BSB premium content.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, plus an expert interview from a cellular therapy specialist in stealth mode, subscribers can log-in or you can click to gain access to BSB Premium Content.
At the start of the New Year, Dr Carl June (@carlhjune) who needs no introduction as one of pioneers of Chimeric Antigen Receptor (CAR) T cell therapy tweeted that, “2020 will be the decade of cell therapy and genome engineering.”
So what does the next decade hold for CAR T cell therapy?
At the recent 2nd European CAR T cell meeting, jointly organized by EHA and EBMT, we asked the man himself to tell us more about his vision.
In Sitges, Dr June kindly spoke to BSB and shared his thoughts on where he sees the CAR T field going, some of the key challenges that will need to be overcome, as well as some of the opportunities to watch out for.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, and a global expert interview from a CAR T cell therapy specialist, subscribers can log-in or you can click to gain access to BSB Premium Content.
When should someone receive CAR T cell therapy? How do we identify who will benefit most or who will be most likely to fail? Those are some of the questions we’re considering in our latest expert interview.
As we see the landscapes around aggressive lymphomas and multiple multiple evolve and change with more near-term CAR T cell therapy approvals coming, so too do the clinical questions surrounding the optimising of these novel approaches.
Prof John Gribben, President of EHA (right) at CART2020 in Sitges
At the EHA/EBMT 2nd European meeting on CAR T cell therapy, BSB spoke with Professor John Gribben. He’s the current President of the European Hematology Association (EHA) and holds the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew’s Hospital, Barts Cancer Institute, Queen Mary, University of London.
One of his messages was when considering CAR T cell therapy, it’s a delicate question of balance.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, and expert interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
Sunrise over Sitges
Sitges – One of the noticeable things about Sitges, a former fishing village south of Barcelona, is the quality of the light. We could imagine it, like St Ives in Cornwall, as being home to artists in times past.
The sunrises and sunsets have been particularly impressive. When it comes to oncology new product development, we’re all chasing the light and the potential of a cure. That’s the promise of cancer immunotherapy.
Here at the 2nd European CAR T cell meeting, jointly organized by EHA and EBMT, we’ve heard about where we’re at with current cell therapies, some of the many challenges that have yet to be overcome and we’ve been offered insights into where some in the field are going.
2020 will be a landmark year for CAR T cell therapy with new regulatory approvals on the horizon, particularly in myeloma, but the journey to make these therapies effective in solid tumours is one where we still need to chase the light.
In this post you can read our notes and commentary on day 2 in Sitges and what caught our attention at the meeting.
To learn more from our oncology coverage and get a heads up on our latest conference analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
Sitges – It’s time to explore new opportunities for cell therapy at the second edition of the European CAR T cell meeting, jointly organized by the European Society for Blood and Marrow Transplantation (EBMT) and European Hematology Association (EHA) kicked off today in Sitges, just south of Barcelona.
With over 1,000 attendees, there’s a lot of interest in the cell therapy field and registrations for the meeting sold out quickly.
That’s not surprising given the impressive line-up of the good and great in the field of cell therapy including Stan Riddell, Carl June, Crystal Mackall, Michel Sadelain, and many others.
There’s also a raft of presentations on the challenges and opportunities for cell therapy, along with presentations of new and emerging approaches in the posters.
In this post you’ll find our reactions and commentary on some of the key messages and insights that emerged and takeaways from the first day at the CAR-T meeting.
To learn more from our oncology coverage and get a heads up on our latest company analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
One of the delights of going to a major medical/scientific meeting such as the recent European Society for Medical Oncology (ESMO) Congress in Barcelona is that there often meetings going on around it, which offer unique and novel perspectives.
For example, on the Thursday before ESMO19 there was a one-day workshop on “Breaking through emergent immunotherapy and immune targets in cancer.”
Dr Manel Juan Otero presenting at the FLS Science symposium
Organized by FLS Science, it took place at the Casa de Convalescència in Barcelona. The program featured a mix of Spanish immunologists and clinicians, along with some leading US researchers including Dr Tom Gajweski (Chicago) and Dr Antoni Ribas (UCLA).
It was definitely well worth attending and I encourage you to look out to see if the organizers run the again meeting before ESMO20 in Madrid next year.
One of the most interesting speakers at the meeting was Dr Manel Juan Otero (right) who heads up the section of immunotherapy at the Hospital Clinic of Barcelona.
In his talk, he spoke about the “Future Directions for CAR-T Therapy” in Spain, which turned out to be a dramatic one with unexpectedly broad European implications.
During a lunch break at the meeting, Dr Juan Otero kindly spoke to BSB about his plans, which could have an impact on commercial CAR T cell therapy companies such as Novartis and Gilead.
To learn more from our coverage on breast cancer and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
This is an extended update that I’ve been planning to write for some time, however, there was always some shiny new clinical data to highlight and discuss so it sadly stayed on the backburner!
Is the sun rising on CAR-T cell threats from the East?
Over the next few weeks, we will post some meaty reviews on various topics pertinent to cancer research R&D. They might involve a particular tumour type that is seeing extensive developments, an important or difficult target, or even a particular category approach, for example.
In the first of this new mini-series, we take a look at the CAR-T cell therapy niche and highlight some important new developments that are well worth watching out for.
Things are a-changin’ very rapidly here, including numerous R&D threats from the east (China) so it’s a good opportunity to take stock and look forward.
Here we go – hold on to your hats…
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Now that at two CAR T cell therapies have been approved by the FDA in two indications, what does the future hold for new developments in both hematologic malignancies and solid tumours?
It was astonishing to explore the poster halls at AACR last month and see just how many new players and targets are emerging left, right and centre.
Last week we highlighted an up and coming new player on the scene, Mustang Bio, but what about the original pioneers in this niche and what are they up to these days?
To answer this question, we tracked down Dr Renier Brentjens at Memorial Sloan Kettering while in Chicago to learn more about his latest work and where he sees the future of CAR T cell therapy heading. It makes for a very interesting, and at times, surprising read…
To learn more and get a heads up on our latest thought leader interview and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At the recent AACR meeting in Chicago one thing that was a surprise was how many new players seem to be emrging in the CAR-T cell space, not to mention the plethora of targets being evaluated preclinically in both hematologic malignancies and solid tumours.
The CAR-T cell niche is becoming very competitive and gritty
If we thought the market was becoming competitive before with less than a dozen players, imagine how crowded it will get once many of the unknowns start to make their mark?
This situation also presents many challenges and opportunities for the new entrants, not just in terms of merely identifying new targets and preclinical research, but also in the need for quality control and manufacturing expertise plus clinical development.
We should also remember that immunotherapy is designed not to target the tumour per se but unleashes the immune system on the tumour. This means that lessons from one approach (e.g. checkpoint therapy) can be applied to another (e.g. CAR-T cell therapy) and vice versa.
Yesterday, we discussed CD123 from the perspective of a bispecific company, what about approaching the target with a CAR-T cell therapy? What other alternative targets are out that that may be useful to investigate in the clinic?
We decided to explore these issues through the lens of one of the up and coming players in the CAR-T cell niche and find out more about what they are doing, how they see things evolving in this dynamic environment and what their path to market strategy is…
To learn more from our latest thought leader interview and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.